176 related articles for article (PubMed ID: 26391697)
1. Pharmacokinetics, Efficacy, and Safety of the Preservative-free Fixed Combination of Tafluprost 0.0015% and Timolol 0.5% in Healthy Volunteers: A Phase I Comparison vs. the Corresponding Preservative-free Monotherapies.
Kaarniranta K; Ikäheimo K; Mannermaa E; Ropo A
Clin Pharmacokinet; 2016 Apr; 55(4):485-94. PubMed ID: 26391697
[TBL] [Abstract][Full Text] [Related]
2. A 6-month study comparing efficacy, safety, and tolerability of the preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% versus each of its individual preservative-free components.
Pfeiffer N; Traverso CE; Lorenz K; Saarela V; Liinamaa J; Uusitalo H; Astakhov Y; Boiko E; Ropo A;
Adv Ther; 2014 Dec; 31(12):1228-46. PubMed ID: 25447269
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, efficacy and safety profiles of preserved and preservative-free tafluprost in healthy volunteers.
Uusitalo H; Kaarniranta K; Ropo A
Acta Ophthalmol Suppl (Oxf ); 2008; 242():7-13. PubMed ID: 18752509
[TBL] [Abstract][Full Text] [Related]
4. Advantages of Efficacy and Safety of Fixed-Dose Tafluprost/Timolol Combination Over Fixed-Dose Latanoprost/Timolol Combination.
Fuwa M; Ueda K; Akaishi T; Yamashita N; Kirihara T; Shimazaki A; Mano H; Kawazu K
PLoS One; 2016; 11(7):e0158797. PubMed ID: 27383260
[TBL] [Abstract][Full Text] [Related]
5. Changes in ocular signs and symptoms in patients switching from bimatoprost-timolol to tafluprost-timolol eye drops: an open-label phase IV study.
Bourne RRA; Kaarniranta K; Lorenz K; Traverso CE; Vuorinen J; Ropo A
BMJ Open; 2019 Apr; 9(4):e024129. PubMed ID: 30944129
[TBL] [Abstract][Full Text] [Related]
6. Benefits of Tafluprost and Timolol Fixed-Dose Combination for the Treatment of Glaucoma Are Confirmed by Studies on Experimental Animal Models.
Akaishi T; Shimazaki A; Tonouchi A; Ueda K; Miyawaki N; Kawazu K
J Ocul Pharmacol Ther; 2015 Nov; 31(9):518-24. PubMed ID: 26325164
[TBL] [Abstract][Full Text] [Related]
7. Randomized clinical trial of the efficacy and safety of preservative-free tafluprost and timolol in patients with open-angle glaucoma or ocular hypertension.
Chabi A; Varma R; Tsai JC; Lupinacci R; Pigeon J; Baranak C; Noble L; Lines C; Ho TW
Am J Ophthalmol; 2012 Jun; 153(6):1187-96. PubMed ID: 22310086
[TBL] [Abstract][Full Text] [Related]
8. Preservative-free tafluprost/timolol fixed combination: comparative 24-h efficacy administered morning or evening in open-angle glaucoma patients.
Konstas AG; Katsanos A; Athanasopoulos GP; Voudouragkaki IC; Panagiotou ES; Pagkalidou E; Haidich AB; Giannoulis DA; Spathi E; Giannopoulos T; Katz LJ
Expert Opin Pharmacother; 2018 Dec; 19(18):1981-1988. PubMed ID: 30328725
[No Abstract] [Full Text] [Related]
9. Preservative-free tafluprost in the treatment of open-angle glaucoma or ocular hypertension in India: a phase III clinical trial.
Chabi A; Baranak C; Lupinacci R; Herring WJ
Int J Clin Pract; 2016 Jul; 70(7):577-86. PubMed ID: 27292765
[TBL] [Abstract][Full Text] [Related]
10. Efficacy, safety, and tolerability of preservative-free fixed combination of tafluprost 0.0015%/timolol 0.5% versus concomitant use of the ingredients.
Holló G; Hommer A; Antón López A; Ropo A
J Ocul Pharmacol Ther; 2014 Aug; 30(6):468-75. PubMed ID: 24738883
[TBL] [Abstract][Full Text] [Related]
11. A comparison of country-level data from the VISIONARY study examining treatment outcomes with preservative-free tafluprost/timolol fixed-dose combination therapy.
Holló G; Kirwan J; Lopez-Lopez F; Zimina M; Fassari C; Oddone F;
Curr Med Res Opin; 2022 Jul; 38(7):1189-1201. PubMed ID: 35621005
[TBL] [Abstract][Full Text] [Related]
12. Preservative-Free Fixed Combination of Tafluprost 0.0015% and Timolol 0.5% for Treatment-Naive Patients with Open-Angle Glaucoma.
Rhee T; Kim J; Ha A
Korean J Ophthalmol; 2024 Jun; 38(3):221-226. PubMed ID: 38665112
[TBL] [Abstract][Full Text] [Related]
13. Intraocular pressure decrease with preservative-free fixed and unfixed combination of tafluprost and timolol in pseudoexfoliative glaucoma.
Holló G; Ropo A
Curr Med Res Opin; 2015 Jan; 31(1):13-6. PubMed ID: 25275411
[TBL] [Abstract][Full Text] [Related]
14. Tafluprost/Timolol: A Review in Open-Angle Glaucoma or Ocular Hypertension.
Hoy SM
Drugs; 2015 Oct; 75(15):1807-13. PubMed ID: 26431840
[TBL] [Abstract][Full Text] [Related]
15. Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: Results from the VISIONARY Study Population in Spain.
Garcia-Medina JJ; Benitez-Del-Castillo J; Rodríguez-Agirretxe I; Lopez-Lopez F; Moreno-Valladares A;
J Ocul Pharmacol Ther; 2022 Apr; 38(3):252-260. PubMed ID: 35230148
[No Abstract] [Full Text] [Related]
16. Safety and tolerability of the tafluprost/timolol fixed combination for the treatment of glaucoma.
Holló G; Katsanos A
Expert Opin Drug Saf; 2015 Apr; 14(4):609-17. PubMed ID: 25640746
[TBL] [Abstract][Full Text] [Related]
17. IOP-lowering efficacy and tolerability of preservative-free tafluprost 0.0015% among patients with ocular hypertension or glaucoma.
Hommer A; Mohammed Ramez O; Burchert M; Kimmich F
Curr Med Res Opin; 2010 Aug; 26(8):1905-13. PubMed ID: 20553122
[TBL] [Abstract][Full Text] [Related]
18. Long term safety and tolerability of Tafluprost 0.0015% vs Timolol 0.1% preservative-free in ocular hypertensive and in primary open-angle glaucoma patients: a cross sectional study.
Rolle T; Spinetta R; Nuzzi R
BMC Ophthalmol; 2017 Aug; 17(1):136. PubMed ID: 28768500
[TBL] [Abstract][Full Text] [Related]
19. Reviewing the evidence surrounding preservative-free tafluprost/timolol fixed-dose combination therapy in open-angle glaucoma and ocular hypertension management: a focus on efficacy, safety, and tolerability.
Oddone F
Expert Opin Drug Saf; 2022 Oct; 21(10):1259-1268. PubMed ID: 36250245
[TBL] [Abstract][Full Text] [Related]
20. Preservative-free tafluprost/timolol fixed combination: a new opportunity in the treatment of glaucoma.
Konstas AG; Holló G
Expert Opin Pharmacother; 2016 Jun; 17(9):1271-83. PubMed ID: 27123557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]